Toggle light / dark theme

The batteries will offer more range in the same size pack, but the automaker still has to solve the technology’s life-span problem.


Toyota has chosen to focus on hybrid and hydrogen fuel-cell vehicles as the cornerstones of its green strategy, but that doesn’t mean the automaker is forgoing an electric vehicle altogether. In addition to an EV crossover coming from the automaker and its partner Subaru in the near future and a lineup of six EVs (some of which are pictured above), which are likely to land in China first, Toyota is currently working on a technological breakthrough that will reach far beyond its use in an EV: the solid-state battery.

Researchers perfect a battery that will let electric vehicles charge faster and drive farther while lasting a lot longer, but don’t expect to see it anytime soon.


For years, solid-state batteries have been heralded as the answer to many of the issues surrounding EVs. The battery technology allows for greater energy density, which translates into more range from the same size pack as a lithium-ion battery. The problem has been that the failure rate is far too high after repeated charging. Also, they’re super expensive. But Samsung may have solved the first issue.

BOSTON, July 27, 2020 /PRNewswire/ — Solid-state batteries keep on attracting tremendous attention and investment with the maturing technologies and closeness to mass production. Even with the influence of COVID-19, the potential market size is expected to grow to over $6 billion by 2030, according to IDTechEx’s report “Solid-State and Polymer Batteries 2020–2030: Technology, Patents, Forecasts, Players.”

A Chinese virologist who has alleged that COVID-19 was human-made in a lab in China released a report on Monday that she says backs up her explosive claim.

Dr. Li-Meng Yan, a former researcher at the Hong Kong School of Public Health, posted a paper on the open-access repository website Zenote, that she claims shows how SARS-CoV-2 could be “conveniently created” in a laboratory setting in six months.

The paper, co-authored with two others, is titled “Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route.”

Medical Ethics and “Futility” (Note: Listen here function)


We breathe about 12 to 20 times a minute, without having to think. Inhale: and air flows through the mouth and nose, into the trachea. The bronchi stem out like a wishbone, and keep branching, dividing and dividing, and finally feeding out into the tiny air sacs of alveoli. Capillaries – blood vessels thinner than hairs – twine around each alveolus. Both the air sac and the blood vessel are tiny, delicate, one cell thick: portals where blood (the atmosphere of the body) meets air (atmosphere of the world). Oxygen passes from air to blood; carbon dioxide, from blood to air. Then, the exhale pushes that carbon dioxide back out the mouth and nose. Capillaries channel newly oxygenated blood back to the heart. That oxygen fuels the body. That’s why we breathe.

Today, these basics of human respiration and metabolism feel obvious – and ventilators, the machines that breathe for sick people, do, too. We have so many medical devices, so of course we’d need, and have, machines that help us to breathe. But there’s a strange, and deeply human, story behind how we learned to breathe for each other. It starts long ago, when we didn’t understand breathing at all. When the body’s failure to breathe was incomprehensible, incurable, and fatal. When we had no way of knowing how badly we needed ventilators to keep people alive through those moments of vulnerability, lest those moments be their last.

Medical TV shows have accustomed us to the sight of doctors moving quickly to keep the sickest patients alive – but that link between hurry and success hasn’t always existed. Up to 100-odd years ago, for most of human history, when doctors had a dying patient, they rushed to do what they knew, but the patient died anyway. It doesn’t matter if you hurry or move slowly if your ‘cures’ don’t work. Ventilation, the linchpin of critical care medicine, changed that. Doctors could save some of the dying. That new technology helped bring medicine from hopes and crossed fingers to saving lives.

At our first online conference, Ending Age-Related Diseases 2020, Dr. Brian Kennedy of the National University of Singapore discussed the aging population of Singapore, the need for comprehensive healthcare, alpha-ketoglutarate and its effects against frailty in mice, ongoing trials of ketoglutarate in humans, spermidine against obesity, the role of biomarkers, and the importance of keeping people well rather than simply treating them when they are sick.